ORION CORPORATION PRESS RELEASE 11 APRIL 2019
A small fire broke out at Orion’s manufacturing plant in Turku late at night on Wednesday 10 April 2019. The fire was in a single piece of production equipment that was temporarily out of production use. The fire was quickly brought under control, and no one was injured and there was no significant material damage. Production will soon be able to return to normal.
Terhi Ormio, Vice President, Communications, tel. +358 50 966 4646
Orionintie 1A, FI-02200 Espoo, Finland
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory diseases for which Orion develops inhaled Easyhaler® pulmonary drugs. Orion's net sales in 2018 amounted to EUR 977 million and the company had about 3,200 employees at the end of the year. Orion’s A and B shares are listed on Nasdaq Helsinki.